Bone Biologics, based in Burlington, Mass., is a publicly traded company focused on orthobiologic solutions.
Here are six things to know.
1. The company's proprietary platform technology is NELL-1, a recombinant human protein growth factor. Bone Biologics' lead product is a NELL-1-based bone graft substitute for spinal fusion.
2. Chia Soo, MD, along with Kang Ting, DMD, and Benjamin Wu, DDS, PhD, founded the company in 2004.
3. The Musculoskeletal Transplant Foundation acquired Bone Biologics in 2006. Since the acquisition, MTF has been the major shareholder and primary funder.
4. The company offers NELL-1 in combination with DBX, a proprietary demineralized bone matrix from the Musculoskeletal Transplant Foundation.
5. Stephen R. La Neve has served as Bone Biologics' CEO and president since 2015. He previously served as president of Medtronic's $3.5 billion Spine and Biologics business.
6. Bone Biologics added osteoporosis and trauma to its portfolio in 2017.
More articles on biologics:
Dr. Luga Podesta on stem cells in orthopedics, 'a new frontier in medicine'
Who are the 15 major players in the global orthobiologics market?
Tissue Regenix group inks deal, expands DermaPure access in US